On or off target: Mutations, models, and predictions

Science Translational Medicine

Volumn 2, Issue 35, 2010, Pages

  Garraway, Levi A ^a   Hahn, William C ^b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; B RAF KINASE INHIBITOR; PLX 4720; SORAFENIB; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR;

AMINO ACID SUBSTITUTION; CANCER INHIBITION; DNA SEQUENCE; DRUG MECHANISM; DRUG PROTEIN BINDING; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; GENE MUTATION; MELANOMA; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; SHORT SURVEY; TRANSLATIONAL RESEARCH; ANIMAL; BIOLOGICAL MODEL; CHEMICAL STRUCTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; GENETICS; HUMAN; MOUSE; MUTATION; NEOPLASM; NOTE;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; MICE; MODELS, BIOLOGICAL; MODELS, MOLECULAR; MUTATION; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 77955615232     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3001263     Document Type: Short Survey

References (10)

1. S. Whittaker, R. Kirk, R. Hayward, A. Zambon, A. Viros, N. Cantarino, A. Affolter, A. Nourry, D. Niculescu-Duvaz, C. Springer, R. Marais, Gatekeeper mutations mediate resistance to BRAF targeted therapies. Sci. Transl. Med. 2, 35ra41 (2010).
2. H. Davies, G. R. Bignell, C. Cox, P. Stephens, S. Edkins, S. Clegg, J. Teague, H. Woffendin, M. J. Garnett, W. Bottomley, N. Davis, E. Dicks, R. Ewing, Y. Floyd, K. Gray, S. Hall, R. Hawes, J. Hughes, V. Kosmidou, A. Menzies, C. Mould, A. Parker, C. Stevens, S. Watt, S. Hooper, R. Wilson, H. Jayatilake, B. A. Gusterson, C. Cooper, J. Shipley, D. Hargrave, K. Pritchard-Jones, N. Maitland, G. Chenevix-Trench, G. J. Riggins, D. D. Bigner, G. Palmieri, A. Cossu, A. Flanagan, A. Nicholson, J. W. Ho, S. Y. Leung, S. T. Yuen, B. L. Weber, H. F. Seigler, T. L. Darrow, H. Paterson, R. Marais, C. J. Marshall, R. Wooster, M. R. Stratton, P. A. Futreal, Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
3. C. Wellbrock, L. Ogilvie, D. Hedley, M. Karasarides, J. Martin, D. Niculescu-Duvaz, C. J. Springer, R. Marais, V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338-2342 (2004).
4. M. Karasarides, A. Chiloeches, R. Hayward, D. Niculescu-Duvaz, I. Scanlon, F. Friedlos, L. Ogilvie, D. Hedley, J. Martin, C. J. Marshall, C. J. Springer, R. Marais, B-RAF is a therapeutic target in melanoma. Oncogene 23, 6292-6298 (2004).
5. D. B. Solit, L. A. Garraway, C. A. Pratilas, A. Sawai, G. Getz, A. Basso, Q. Ye, J. M. Lobo, Y. She, I. Osman, T. R. Golub, J. Sebolt-Leopold, W. R. Sellers, N. Rosen, BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358-362 (2006).
6. A. Hauschild, S. S. Agarwala, U. Trefzer, D. Hogg, C. Robert, P. Hersey, A. Eggermont, S. Grabbe, R. Gonzalez, J. Gille, C. Peschel, D. Schadendorf, C. Garbe, S. O'Day, A. Daud, J. M. White, C. Xia, K. Patel, J. M. Kirkwood, U. Keilholz, Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma. J. Clin. Oncol. 27, 2823-2830 (2009).
7. T. Eisen, T. Ahmad, K. T. Flaherty, M. Gore, S. Kaye, R. Marais, I. Gibbens, S. Hackett, M. James, L. M. Schuchter, K. L. Nathanson, C. Xia, R. Simantov, B. Schwartz, M. Poulin-Costello, P. J. O'Dwyer, M. J. Ratain, Sorafenib in advanced melanoma: A Phase II randomised discontinuation trial analysis. Br. J. Cancer 95, 581-586 (2006).
8. M. E. Gorre, M. Mohammed, K. Ellwood, N. Hsu, R. Paquette, P. N. Rao, C. L. Sawyers, Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
9. S. Kobayashi, T. J. Boggon, T. Dayaram, P. A. Jänne, O. Kocher, M. Meyerson, B. E. Johnson, M. J. Eck, D. G. Tenen, B. Halmos, EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352, 786-792 (2005).
10. Competing interests: W.C.H. and L.A.G. are paid consultants for Novartis. L.A.G. has filed patent applications that describe resistance-conferring BRAF mutations; however, the mutations described herein were not included.